Tian Zhang
Assistant Professor of Medicine
Current Appointments & Affiliations
- Assistant Professor of Medicine, Medicine, Medical Oncology, Medicine 2017
- Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 2015
Contact Information
- DUMC 103861, Durham, NC 27710
- Dept Of Medicine, Box 103861, Durham, NC 27710
-
tian.zhang2@duke.edu
(919) 668-4667
- Background
-
Education, Training, & Certifications
- Fellowship in Hematology-Oncology, Medicine, Duke University School of Medicine 2012 - 2015
- Internal Medicine Residency, Medicine, Duke University School of Medicine 2009 - 2012
- M.D., Harvard Medical School 2009
-
Duke Appointment History
- Medical Instructor in the Department of Medicine, Medicine, Medical Oncology, Medicine 2015 - 2017
- Research
-
Selected Grants
- A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) awarded by Merck 2018 - 2023
- A Salvage Trial of AR Inhibition with ADT and Apalutamide with Docetaxel followed by Radiation Therapy in Men with PSA Recurrent Prostate Cancer after Radical Prostatectomy (¿STARTAR¿) awarded by Janssen Pharmaceutica, Inc. 2018 - 2023
- Merrimack MM-310-01-01-01 awarded by Merrimack Pharmaceuticals 2017 - 2022
- An Open-Label Study of Rovalpituzumab awarded by AbbVie Inc. 2017 - 2022
- Phase II study of AGS-16C3F vs Axitinib in Metastatic Renal Cell Carcinoma awarded by Astellas Pharma Global Development, Inc 2016 - 2021
- Pfizer VBIR awarded by Pfizer, Inc. 2016 - 2021
- A Retrospective Study to Evaluate the Clinical Effectiveness of the OmniSeq Immune Advance Test to Predict Response to Checkpoint Inhibitors awarded by OmniSeq, Inc 2017 - 2019
- A study is to develop a retrospective database to study the PGDx TMB +MSI assay associated with clinical responses to immune checkpoint inhibitors (CPIs) awarded by Personal Genome Diagnostics, Inc. 2017 - 2019
- A Phase 1b, open label, prospective, non-randomized,single center study of conditional lethalithy to copper as a therapeutic modality in prostate cancer awarded by Cantex Pharmaceuticals, Inc. 2017 - 2019
- Retrospective analysis of docetaxel in castration sensitive setting awarded by H. Lee Moffitt Cancer Center & Research Institute 2017 - 2019
- CTC-Immune Checkpoints awarded by Janssen Research & Development, LLC 2016 - 2019
- A Phase I/II open label multicenter study of the safety and efficacy of LAG525 single agent in combination with PDR001 adminitered to patients awarded by Novartis Pharmaceuticals Corporation 2015 - 2018
- Conditional lethality of copper and disulfiram as a therapeutic modality for prostate cancer awarded by V Foundation for Cancer Research 2016 - 2018
- Publications & Artistic Works
-
Selected Publications
-
Book Sections
- Zhang, T, and Wang, AZ. "Biochemical failure in prostate cancer." In Prostate Cancer: A Comprehensive Perspective, 807-811. July 1, 2013. Full Text
-
Journal Articles
- Humeniuk, MS, Gupta, RT, Healy, P, McNamara, M, Ramalingam, S, Harrison, M, George, D, Zhang, T, Wu, Y, and Armstrong, AJ. "Platinum sensitivity in metastatic prostate cancer: does histology matter?." Prostate cancer and prostatic diseases 21, no. 1 (April 2018): 92-99. Full Text
- Myung, JH, Eblan, MJ, Caster, JM, Park, S, Poellmann, MJ, Wang, K, Tepper, JE, Tam, KA, Miller, SM, Shen, C, Chen, RC, Zhang, T, Chera, B, Wang, AZ, and Hong, S. "Multivalent binding and biomimetic cell rolling improves the sensitivity and specificity of circulating tumor cell capture." Clinical cancer research : an official journal of the American Association for Cancer Research (March 15, 2018). Full Text
- Koshkin, VS, Barata, PC, Zhang, T, George, DJ, Atkins, MB, Kelly, WJ, Vogelzang, NJ, Pal, SK, Hsu, J, Appleman, LJ, Ornstein, MC, Gilligan, T, Grivas, P, Garcia, JA, and Rini, BI. "Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma." Journal for immunotherapy of cancer 6, no. 1 (January 29, 2018): 9-. Full Text Open Access Copy
- Zhu, J, Armstrong, AJ, Friedlander, TW, Kim, W, Pal, SK, George, DJ, and Zhang, T. "Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond." Journal for immunotherapy of cancer 6, no. 1 (January 25, 2018): 4-. (Review) Full Text Open Access Copy
- Garland Austin, R, Huang, TJ, Wu, M, Armstrong, AJ, and Zhang, T. "Clinical utility of non-EpCAM based circulating tumor cell assays." Advanced drug delivery reviews (January 20, 2018). Full Text
- Zhu, J, Tucker, M, Wang, E, Grossman, JS, Armstrong, AJ, George, DJ, and Zhang, T. "Acute Myeloid Leukemia After Olaparib Treatment in Metastatic Castration-Resistant Prostate Cancer." Clinical genitourinary cancer 15, no. 6 (December 2017): e1137-e1141. Full Text
- Zhang, T, and Armstrong, AJ. "The Who, What, and How of Cabazitaxel Treatment in Metastatic Castration-Resistant Prostate Cancer." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 35, no. 28 (October 2017): 3175-3177. Full Text
- Zhang, T, and Armstrong, AJ. "The who, what, and how of cabazitaxel treatment in metastatic castration-resistant prostate cancer." Journal of Clinical Oncology 35, no. 28 (October 1, 2017): 3175-3177. Full Text
- Humeniuk, MS, Zhang, T, and Armstrong, AJ. "Exploiting DNA damage without repair: The activity of platinum chemotherapy in BRCA-mutated prostate cancers." Cancer 123, no. 18 (September 2017): 3441-3444. Full Text
- Min, Y, Roche, KC, Tian, S, Eblan, MJ, McKinnon, KP, Caster, JM, Chai, S, Herring, LE, Zhang, L, Zhang, T, DeSimone, JM, Tepper, JE, Vincent, BG, Serody, JS, and Wang, AZ. "Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy." Nature nanotechnology 12, no. 9 (September 2017): 877-882. Full Text
- Ramalingam, S, Humeniuk, MS, Hu, R, Rasmussen, J, Healy, P, Wu, Y, Harrison, MR, Armstrong, AJ, George, DJ, and Zhang, T. "Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer." Urologic oncology 35, no. 6 (June 2017): 418-424. Full Text
- Tian, J, Min, Y, Rodgers, Z, Wan, X, Qiu, H, Mi, Y, Tian, X, Wagner, KT, Caster, JM, Qi, Y, Roche, K, Zhang, T, Cheng, J, and Wang, AZ. "Nanoparticle delivery of chemotherapy combination regimen improves the therapeutic efficacy in mouse models of lung cancer." Nanomedicine : nanotechnology, biology, and medicine 13, no. 3 (April 2017): 1301-1307. Full Text
- Zhang, T, Park, SE, Hong, C, and George, DJ. "Cabozantinib in genitourinary malignancies." Future oncology (London, England) 13, no. 8 (April 2017): 755-765. (Review) Full Text
- Caster, JM, Patel, AN, Zhang, T, and Wang, A. "Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials." Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology 9, no. 1 (January 2017). (Review) Full Text
- Zhang, T, Gong, J, Maia, MC, and Pal, SK. "Systemic Therapy for Non-Clear Cell Renal Cell Carcinoma." American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting 37 (January 2017): 337-342. Full Text
- Tian, X, Warner, SB, Wagner, KT, Caster, JM, Zhang, T, Ohana, P, Gabizon, AA, and Wang, AZ. "Preclinical Evaluation of Promitil, a Radiation-Responsive Liposomal Formulation of Mitomycin C Prodrug, in Chemoradiotherapy." International journal of radiation oncology, biology, physics 96, no. 3 (November 2016): 547-555. Full Text
- Zhang, T, Zhu, J, George, DJ, and Nixon, AB. "Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies." Urologic oncology 34, no. 11 (November 2016): 510-518. (Review) Full Text
- Shao, Z, Wang, AZ, George, DJ, and Zhang, T. "Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma." Asian journal of urology 3, no. 4 (October 2016): 268-277. (Review) Full Text
- Hu, R, George, DJ, and Zhang, T. "What is the role of sipuleucel-T in the treatment of patients with advanced prostate cancer? An update on the evidence." Therapeutic advances in urology 8, no. 4 (August 2016): 272-278. (Review) Full Text
- Kamal, A, Zhang, T, Power, S, and Marcom, PK. "Is Advanced Imaging in Early-Stage Breast Cancer Ever Warranted? Reconciling Clinical Judgment With Common Quality Measures." Journal of the National Comprehensive Cancer Network : JNCCN 14, no. 8 (August 2016): 993-998. Full Text
- Kamal, A, Zhang, T, Power, S, and Marcom, PK. "Is advanced imaging in early-stage breast cancer ever warranted? Reconciling clinical judgment with common quality measures." JNCCN Journal of the National Comprehensive Cancer Network 14, no. 8 (August 1, 2016): 993-998. Full Text
- Ware, KE, Somarelli, JA, Schaeffer, D, Li, J, Zhang, T, Park, S, Patierno, SR, Freedman, J, Foo, W-C, Garcia-Blanco, MA, and Armstrong, AJ. "Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer." Oncotarget 7, no. 31 (August 2016): 50507-50521. Full Text Open Access Copy
- Zhang, T, Boominathan, R, Foulk, B, Rao, C, Kemeny, G, Strickler, JH, Abbruzzese, JL, Harrison, MR, Hsu, DS, Healy, P, Li, J, Pi, C, Prendergast, KM, Hobbs, C, Gemberling, S, George, DJ, Hurwitz, HI, Connelly, M, Garcia-Blanco, MA, and Armstrong, AJ. "Development of a Novel c-MET-Based CTC Detection Platform." Molecular cancer research : MCR 14, no. 6 (June 2016): 539-547. Full Text Open Access Copy
- Au, KM, Satterlee, A, Min, Y, Tian, X, Kim, YS, Caster, JM, Zhang, L, Zhang, T, Huang, L, and Wang, AZ. "Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: Turning a bone antiresorptive agent into an anticancer therapeutic." Biomaterials 82 (March 2016): 178-193. Full Text
- Zhu, J, Davis, CT, Silberman, S, Spector, N, and Zhang, T. "A role for the androgen receptor in the treatment of male breast cancer." Critical reviews in oncology/hematology 98 (February 2016): 358-363. (Review) Full Text
- Zhang, T, and Armstrong, AJ. "Clinical Utility of Circulating Tumor Cells in Advanced Prostate Cancer." Current oncology reports 18, no. 1 (January 2016): 3-. (Review) Full Text
- Zhu, J, Zhang, T, Shah, R, Kamal, AH, and Kelley, MJ. "Comparison of Quality Oncology Practice Initiative (QOPI) Measure Adherence Between Oncology Fellows, Advanced Practice Providers, and Attending Physicians." Journal of cancer education : the official journal of the American Association for Cancer Education 30, no. 4 (December 2015): 774-778. Full Text
- Zhang, T, and Armstrong, AJ. "Docetaxel Resistance in Prostate Cancer: Taking It Up a Notch." Clinical cancer research : an official journal of the American Association for Cancer Research 21, no. 20 (October 2015): 4505-4507. Full Text Open Access Copy
- Zhang, T, Dhawan, MS, Healy, P, George, DJ, Harrison, MR, Oldan, J, Chin, B, and Armstrong, AJ. "Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer." Clinical genitourinary cancer 13, no. 4 (August 2015): 392-399. Full Text
- Zhang, T, Boswell, EL, McCall, SJ, and Hsu, DS. "Mismatch repair gone awry: Management of Lynch syndrome." Critical reviews in oncology/hematology 93, no. 3 (March 2015): 170-179. (Review) Full Text
- Zhang, T, Zhu, J, George, DJ, and Armstrong, AJ. "Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer." Expert opinion on pharmacotherapy 16, no. 4 (March 2015): 473-485. (Review) Full Text
- Zhu, J, Zhang, T, Shah, R, Kamal, AH, and Kelley, MJ. "Comparison of Quality Oncology Practice Initiative (QOPI) Measure Adherence Between Oncology Fellows, Advanced Practice Providers, and Attending Physicians." Journal of Cancer Education 30, no. 4 (2015): 774-778. Full Text
- Aggarwal, R, Zhang, T, Small, EJ, and Armstrong, AJ. "Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes." Journal of the National Comprehensive Cancer Network : JNCCN 12, no. 5 (May 2014): 719-726. (Review) Full Text
- Boggan, JC, Zhang, T, Derienzo, C, Frush, K, and Andolsek, K. "Standardizing and Evaluating Transitions of Care in the Era of Duty Hour Reform: One Institution's Resident-Led Effort." Journal of graduate medical education 5, no. 4 (December 2013): 652-657. Full Text
- Zhang, T, Das, SK, Fels, DR, Hansen, KS, Wong, TZ, Dewhirst, MW, and Vlahovic, G. "PET with 62Cu-ATSM and 62Cu-PTSM is a useful imaging tool for hypoxia and perfusion in pulmonary lesions." AJR. American journal of roentgenology 201, no. 5 (November 2013): W698-W706. Full Text
- Zhang, T, and Armstrong, AJ. "Clinical phenotypes of castration-resistant prostate cancer." Clinical advances in hematology & oncology : H&O 11, no. 11 (November 2013): 707-718. (Review)
- Zhang, T, Schneider, A, Hamilton, EP, Patel, K, Kamal, AH, Lyman, GH, and Peppercorn, JM. "Prevalence and impact of correlative science in breast cancer phase II trials." Breast Cancer Res Treat 139, no. 3 (June 2013): 845-850. Full Text Link to Item
- Zhang, T, Schneider, A, Hamilton, EP, Patel, K, Kamal, AH, Lyman, GH, and Peppercorn, JM. "Prevalence and impact of correlative science in breast cancer phase II trials." Breast Cancer Research and Treatment 139, no. 3 (2013): 845-850. Full Text
- DeRienzo, CM, Frush, K, Barfield, ME, Gopwani, PR, Griffith, BC, Jiang, X, Mehta, AI, Papavassiliou, P, Rialon, KL, Stephany, AM, Zhang, T, Andolsek, KM, and Duke University Health System Graduate Medical Education Patient Safety and Quality Council, . "Handoffs in the era of duty hours reform: a focused review and strategy to address changes in the Accreditation Council for Graduate Medical Education Common Program Requirements." Academic medicine : journal of the Association of American Medical Colleges 87, no. 4 (April 2012): 403-410. (Review) Full Text
- Werner, ME, Karve, S, Sukumar, R, Cummings, ND, Copp, JA, Chen, RC, Zhang, T, and Wang, AZ. "Folate-targeted nanoparticle delivery of chemo- and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis." Biomaterials 32, no. 33 (November 2011): 8548-8554. Full Text
- Kamal, A, Zhang, T, Schneider, A, Patel, K, Hamilton, EP, Marcom, PK, and Peppercorn, JM. "Outcomes in phase II trials of metastatic breast cancer: Where is the bar?." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 29, no. 15_suppl (May 2011): 2590-.
- Patel, K, Kamal, A, Zhang, T, Schneider, A, Hamilton, EP, and Peppercorn, JM. "The role of biologic therapy in phase II breast cancer clinical trials." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 29, no. 15_suppl (May 2011): e13048-.
- Schneider, A, Zhang, T, Kamal, A, Patel, K, Hamilton, EP, and Peppercorn, JM. "Pharmaceutical involvement in phase II breast cancer clinical trials." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 29, no. 15_suppl (May 2011): 6104-.
- Zhang, T, Hamilton, EP, Schneider, A, Patel, K, Kamal, A, and Peppercorn, JM. "Prevalence and impact of correlative science in breast cancer phase II trials." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 29, no. 15_suppl (May 2011): 1046-.
-
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.
